Insulin detemir is an effective long-acting human insulin analogue for the treatment of type 1 and 2 diabetes mellitus

被引:0
|
作者
不详
机构
关键词
D O I
10.2165/00042310-200521090-00001
中图分类号
学科分类号
摘要
Insulin detemir is a long-acting insulin analogue with slow absorption and a prolonged and consistent metabolic effect. Insulin detemir has a more predictable glucose-lowering effect than insulin suspension isophane (neutral protamine Hagedorn insulin), and less intrapatient variability in glycaemic control than insulin glargine. In comparative trials, insulin detemir was at least as effective as insulin suspension isophane in maintaining glycaemic control and reduced the risk of bodyweight gain in patients with diabetes. Comparative studies with insulin glargine are not yet available. Insulin detemir is as well tolerated as insulin suspension isophane with a similar or lower risk of hypoglycaemia, especially nocturnal hypoglycaemia. © 2005 Adis Data Information BV. All rights reserved.
引用
收藏
页码:1 / 4
页数:3
相关论文
共 50 条
  • [1] Treatment of Type 1 and Type 2 Diabetes Mellitus with Insulin Detemir, a Long-Acting Insulin Analog
    Young, Jason R.
    McAdam-Marx, Carrie
    [J]. CLINICAL MEDICINE INSIGHTS-ENDOCRINOLOGY AND DIABETES, 2010, 3 : 65 - 80
  • [2] An update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog
    Raslova, Katarina
    [J]. VASCULAR HEALTH AND RISK MANAGEMENT, 2010, 6 : 399 - 410
  • [3] The mechanism of protraction of insulin detemir, a long-acting, acylated analogue of human insulin
    Havelund, S
    Ribel, U
    Plum, A
    Jonassen, IB
    Volund, A
    Markussen, J
    Kurtzhals, P
    [J]. DIABETES, 2004, 53 : A109 - A109
  • [4] COMPARATIVE COST-UTILITY ANALYSIS OF LONG-ACTING INSULIN ANALOGUE (INSULIN DETEMIR) AND NPH INSULIN FOR THE TREATMENT OF TYPE 1 AND TYPE 2 DIABETES AND THE BUDGET IMPACT ANALYSIS OF INSULIN ANALOGUE REIMBURSEMENT IN POLAND
    Walczak, J.
    Pawlik, D.
    Jasinska, A.
    Garbacka, M.
    Kedzior, J.
    Fundament, T.
    Malczak, I
    Dardzinski, W.
    Skrzekowska-Baran, I
    Czech, M.
    Nogas, G.
    [J]. VALUE IN HEALTH, 2008, 11 (06) : A500 - A500
  • [5] Long-acting insulin analogue detemir compared with NPH insulin in type 1 diabetes A systematic review and meta-analysis
    Szypowska, Agnieszka
    Golicki, Dominik
    Groele, Lidia
    Pankowska, Ewa
    [J]. POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ-POLISH ARCHIVES OF INTERNAL MEDICINE, 2011, 121 (7-8): : 237 - 246
  • [6] The effect of long-acting insulin analogues, glargine or detemir, in Type 2 diabetes
    Dissanayake, S.
    Balakrisna-Rao, P.
    Ahmed, A. B.
    [J]. DIABETIC MEDICINE, 2007, 24 : 75 - 75
  • [7] Insulin therapy in type 2 diabetes:: role of the long-acting insulin glargine analogue
    Yki-Järvinen, H
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2004, 34 (06) : 410 - 416
  • [8] Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus
    Horvath, K.
    Jeitler, K.
    Berghold, A.
    Ebrahim, S. H.
    Gratzer, T. W.
    Plank, J.
    Kaiser, T.
    Pieber, T. R.
    Siebenhofer, A.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2007, (02):
  • [9] Insulin detemir: A long-acting insulin product
    Jones, Melissa C.
    Patel, Mallika
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2006, 63 (24) : 2466 - 2472
  • [10] Insulin Degludec, a Long-Acting Once-Daily Basal Analogue for Type 1 and Type 2 Diabetes Mellitus
    Berard, Lori
    MacNeill, Gail
    [J]. CANADIAN JOURNAL OF DIABETES, 2015, 39 (01) : 4 - 9